The first ap­proved generic of the mul­ti­ple-scle­ro­sis drug Copax­one, ex­pected to cost $1,000 a month less than the name brand, was launched last week af­ter a fed­eral ap­peals court up­held a rul­ing that drug­maker Teva Phar­ma­ceu­ti­cals’ patent on its best-sell

Modern Healthcare - - LATE NEWS -

Teva fought for years to de­lay generic com­peti­tors to Copax­one, which gen­er­ated $4.8 bil­lion in sales world­wide in 2013. The new generic drug, Glatopa, is be­ing de­vel­oped in the U.S. as part of col­lab­o­ra­tion be­tween No­var­tis sub­sidiary San­doz and Mo­menta Phar­ma­ceu­ti­cals.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.